Drug Profile
Implant-associated infection vaccine - Origimm
Latest Information Update: 08 Dec 2021
Price :
$50
*
At a glance
- Originator Origimm
- Class Antibacterials
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gram-positive infections
Most Recent Events
- 01 Dec 2021 Origimm has been acquired by Sanofi
- 28 Aug 2020 No recent reports of development identified for research development in Gram-positive-infections(Prevention) in Austria
- 13 Jul 2016 Early research in Gram-positive infections (Prevention) in Austria (unspecified route)